• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis.患者和项目因素对耐多药结核病治疗中停药的影响。
Int J Tuberc Lung Dis. 2012 Jul;16(7):955-60. doi: 10.5588/ijtld.11.0502. Epub 2012 May 7.
2
Predictors and mortality associated with treatment default in pulmonary tuberculosis.与肺结核治疗中断相关的预测因素和死亡率。
Int J Tuberc Lung Dis. 2010 Apr;14(4):454-63.
3
Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment.耐多药结核病治疗中断相关的危险因素及死亡率
Clin Infect Dis. 2008 Jun 15;46(12):1844-51. doi: 10.1086/588292.
4
High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003.2000-2003 年南非夸祖鲁-纳塔尔省耐多药结核病患者的高治疗失败率和高失访率。
Int J Tuberc Lung Dis. 2010 Apr;14(4):413-9.
5
Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study.亚美尼亚耐多药结核病治疗中断的原因：一项定量和定性研究。
Int J Tuberc Lung Dis. 2014 Feb;18(2):160-7. doi: 10.5588/ijtld.13.0369.
6
Prevalence and factors associated with non-adherence to multi-drug resistant tuberculosis (MDR-TB) treatment at Mulago National Referral Hospital, Kampala, Uganda.乌干达坎帕拉市穆拉戈国家转诊医院耐多药结核病（MDR-TB）治疗不依从的流行情况及相关因素。
Afr Health Sci. 2021 Mar;21(1):238-247. doi: 10.4314/ahs.v21i1.31.
7
Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005.2002-2005 年俄罗斯奥廖尔耐多药结核病患者的治疗结果和随访。
Int J Tuberc Lung Dis. 2012 Aug;16(8):1069-74. doi: 10.5588/ijtld.11.0696. Epub 2012 Jun 11.
8
Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India.印度孟买贫民窟中感染 HIV 的患者队列中，门诊耐多药结核病治疗结局。
PLoS One. 2011;6(12):e28066. doi: 10.1371/journal.pone.0028066. Epub 2011 Dec 1.
9
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.HIV感染患者中耐多药结核病的预测因素及对特定药物治疗方案的反应。艾滋病临床研究特里·贝恩社区项目（CPCRA）和美国国立卫生研究院艾滋病临床试验组（ACTG）
Int J Tuberc Lung Dis. 1999 Apr;3(4):337-43.
10
Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.印度修订国家结核病控制规划（2007-2011 年）下初始耐多药结核病（MDR-TB）患者中不可接受的治疗结果及相关因素：政策改进的依据。
PLoS One. 2018 Apr 11;13(4):e0193903. doi: 10.1371/journal.pone.0193903. eCollection 2018.

引用本文的文献

1
Exploring health care providers' engagement in prevention and management of multidrug resistant Tuberculosis and its factors in Hadiya Zone health care facilities: qualitative study.探讨哈迪耶地区医疗保健机构中医疗保健提供者参与耐多药结核病的预防和管理及其影响因素：定性研究。
BMC Health Serv Res. 2024 Apr 27;24(1):542. doi: 10.1186/s12913-024-10911-6.
2
Cost-consequence analysis of ambulatory clinic- and home-based multidrug-resistant tuberculosis management models in Eswatini.斯威士兰门诊和家庭为基础的耐多药结核病管理模式的成本-后果分析。
PLoS One. 2024 Apr 2;19(4):e0301507. doi: 10.1371/journal.pone.0301507. eCollection 2024.
3

本文引用的文献

1
A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.抗多药耐药结核病治疗的成本和成本效益的系统评价。
Pharmacoeconomics. 2012 Jan;30(1):63-80. doi: 10.2165/11595340-000000000-00000.
2
Nationwide drug resistance survey of tuberculosis in the Philippines.菲律宾全国结核病耐药性调查。
Int J Tuberc Lung Dis. 2009 Apr;13(4):500-7.
3
Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment.耐多药结核病治疗中断相关的危险因素及死亡率
Why do patients with DR-TB do not complete their treatment? Findings of a qualitative study from Pakistan.
为什么耐多药结核病患者不完成治疗？来自巴基斯坦的定性研究结果。
BMJ Open Respir Res. 2024 Feb 26;11(1):e002186. doi: 10.1136/bmjresp-2023-002186.
4
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.新型联合方案贝达喹啉或 TBAJ-587 联合 GSK2556286 和 TBA-7371 在结核分枝杆菌感染小鼠模型中的杀菌和灭菌活性。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0156223. doi: 10.1128/aac.01562-23. Epub 2024 Feb 20.
5
A qualitative exploration of tuberculosis patients who were lost to follow-up in Malaysia.马来西亚失访结核病患者的定性研究。
PLoS One. 2023 Sep 7;18(9):e0289222. doi: 10.1371/journal.pone.0289222. eCollection 2023.
6
Reasons for loss to follow-up (LTFU) of pulmonary TB (PTB) patients: A qualitative study among Saharia, a particularly vulnerable tribal group of Madhya Pradesh, India.印度中央邦特别弱势部落群体萨哈里亚人群肺结核（PTB）患者失访原因的定性研究。
PLoS One. 2021 Dec 23;16(12):e0261152. doi: 10.1371/journal.pone.0261152. eCollection 2021.
7
Between Curing and Torturing: Burden of Adverse Reaction in Drug-Resistant Tuberculosis Therapy.在治愈与折磨之间：耐多药结核病治疗中的不良反应负担
Patient Prefer Adherence. 2021 Nov 23;15:2597-2607. doi: 10.2147/PPA.S333111. eCollection 2021.
8
Assessment of training and mentoring for DR-TB care decentralization in Tanzania.评估坦桑尼亚耐多药结核病护理权力下放的培训和指导情况。
Hum Resour Health. 2021 Apr 26;19(1):56. doi: 10.1186/s12960-021-00600-4.
9
Patient and health-care worker perspectives on the short-course regimen for treatment of drug-resistant tuberculosis in Karakalpakstan, Uzbekistan.患者与医护人员对乌兹别克斯坦卡拉卡尔帕克斯坦耐药结核病短程治疗方案的看法。
PLoS One. 2020 Nov 25;15(11):e0242359. doi: 10.1371/journal.pone.0242359. eCollection 2020.
10
Intermittent treatment interruption and its effect on multidrug resistant tuberculosis treatment outcome in Ethiopia.间歇性治疗中断及其对埃塞俄比亚耐多药结核病治疗结局的影响。
Sci Rep. 2019 Dec 27;9(1):20030. doi: 10.1038/s41598-019-56553-1.
Clin Infect Dis. 2008 Jun 15;46(12):1844-51. doi: 10.1086/588292.
4
Treating multidrug-resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease.俄罗斯托木斯克市耐多药结核病的治疗：制定解决贫困与疾病之间联系的项目。
Ann N Y Acad Sci. 2008;1136:1-11. doi: 10.1196/annals.1425.009. Epub 2007 Oct 22.
5
Default from tuberculosis treatment programme in Sagamu, Nigeria.尼日利亚萨加穆结核病治疗项目中的违约情况。
Niger J Med. 2006 Jan-Mar;15(1):63-7. doi: 10.4314/njm.v15i1.37119.
6
Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study.拉脱维亚耐多药结核病个体化治疗的临床结局：一项回顾性队列研究
Lancet. 2005;365(9456):318-26. doi: 10.1016/S0140-6736(05)17786-1.
7
Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience.秘鲁利马基于社区的耐多药结核病治疗：7年经验
Soc Sci Med. 2004 Oct;59(7):1529-39. doi: 10.1016/j.socscimed.2004.01.027.
8
Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.韩国耐多药结核病的自我管理标准化治疗方案。
Int J Tuberc Lung Dis. 2004 Mar;8(3):361-8.
9
Prevalence and predictors of default from tuberculosis treatment in Hong Kong.香港结核病治疗中断的患病率及预测因素
Hong Kong Med J. 2003 Aug;9(4):263-8.
10
DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed.菲律宾针对耐多药结核病的强化直接督导短程化疗：迫切需要全球援助。
Tuberculosis (Edinb). 2003;83(1-3):52-8. doi: 10.1016/s1472-9792(02)00072-0.

患者和项目因素对耐多药结核病治疗中停药的影响。

Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis.

机构信息

Tropical Disease Foundation, Manila, The Philippines.

出版信息

Int J Tuberc Lung Dis. 2012 Jul;16(7):955-60. doi: 10.5588/ijtld.11.0502. Epub 2012 May 7.

DOI:10.5588/ijtld.11.0502
PMID:22584124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4616015/
Abstract

SETTING

In the Philippines, programmatic treatment of drug-resistant tuberculosis (TB) was initiated by the Tropical Disease Foundation in 1999 and transitioned to the National TB Program in 2006.

OBJECTIVE

To determine patient and socio-demographic characteristics associated with default, and the impact of patient support measures on default.

DESIGN

Retrospective cohort analysis of 583 MDR-TB patients treated from 1999 to 2006.

RESULTS

A total of 88 (15%) patients defaulted from treatment. The median follow-up time for patients who defaulted was 289 days (range 1-846). In multivariate analysis adjusted for age, sex and previous TB treatment, receiving a greater number of treatment drugs (≥ 5 vs. 2-3 drugs, HR 7.2, 95%CI 3.3-16.0, P < 0.001) was significantly associated with an increased risk of default, while decentralization reduced the risk of default (HR 0.3, 95%CI 0.2-0.7, P < 0.001).

CONCLUSION

Improving access to treatment for MDR-TB through decentralization of care to centers near the patient's residence reduced the risk of default. Further research is needed to evaluate the feasibility, impact and cost-effectiveness of decentralized care models for MDR-TB treatment.

摘要

背景

菲律宾热带病基金会于 1999 年启动了耐药结核病（TB）的方案性治疗，并于 2006 年过渡到国家结核病规划。

目的

确定与患者失访相关的患者和社会人口学特征，并评估患者支持措施对失访的影响。

设计

1999 年至 2006 年治疗的 583 例耐多药结核病（MDR-TB）患者的回顾性队列分析。

结果

共有 88 名（15%）患者失访。失访患者的中位随访时间为 289 天（范围 1-846 天）。在调整年龄、性别和既往结核病治疗的多变量分析中，接受更多治疗药物（≥5 种与 2-3 种药物相比，HR7.2，95%CI3.3-16.0，P<0.001）与更高的失访风险显著相关，而分散化治疗降低了失访风险（HR0.3，95%CI0.2-0.7，P<0.001）。

结论

通过将治疗服务分散到患者居住地附近的中心，改善耐多药结核病患者获得治疗的机会，降低了失访的风险。需要进一步研究来评估耐多药结核病治疗分散化治疗模式的可行性、影响和成本效益。